Home Featured Page 291

Featured

Latest

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

Pα+ Psychedelic Bulletin #208: Psychedelic CEOs’ FDA Wish-List; APA Division 56 President Talks Psychedelics; Compass’ PTSD Study Published; Cybin Ousts Drysdale

BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL)

Psychedelic Researchers Respond to FDA’s Push to Reduce Animal Testing

Bridging Worlds: Psychedelics, Community, and the Work of Our Time

DMT Art: A Look Behind Visionary Creations

How to Get DMT: Obtaining the Spirit Molecule

Dr. Carl Hart: Demystifying Drugs

Joe Biden’s Evolution on Drug Policy

Having Sex on DMT: What You Need to Know

This is the Difference Between Psilocybin and LSD

So, You Want to Participate in a Psychedelic Clinical Trial

Psychedelics and Religion: A Short History

How Psychedelics Can Treat Eating Disorders

1...290291292...296 Page 291 of 296

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

Pα+ Psychedelic Bulletin #208: Psychedelic CEOs’ FDA Wish-List; APA Division 56...

BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL)

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

Pα+ Psychedelic Bulletin #208: Psychedelic CEOs’ FDA Wish-List; APA Division 56 President Talks Psychedelics; Compass’ PTSD Study Published; Cybin Ousts Drysdale

BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL)

Psychedelic Researchers Respond to FDA’s Push to Reduce Animal Testing

Bridging Worlds: Psychedelics, Community, and the Work of Our Time

DMT Art: A Look Behind Visionary Creations

Mapping the DMT Experience

How to Get DMT: Obtaining the Spirit Molecule

Dr. Carl Hart: Demystifying Drugs

Joe Biden’s Evolution on Drug Policy

Having Sex on DMT: What You Need to Know

This is the Difference Between Psilocybin and LSD

So, You Want to Participate in a Psychedelic Clinical Trial

Psychedelics and Religion: A Short History

How Psychedelics Can Treat Eating Disorders

EDITOR PICKS

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

Pα+ Psychedelic Bulletin #208: Psychedelic CEOs’ FDA Wish-List; APA Division 56...

BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL)

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY